AZ/Nektar constipation drug Movantik OK'd

Right on schedule, AstraZeneca and partner Nektar on 16 September won the FDA's approval to market Movantik (naloxegol), an oral peripherally active mu opioid receptor antagonist (PAMORA), as a treatment for opioid-induced constipation (OIC) in adults with chronic non-cancer pain.